Preserved SLAMF7 expression, and a different mode of action without cross-resistance to other anti-MM agents, may explain why UCARTCS1 cells had comparable efficacy against primary MM cells in samples from newly diagnosed and heavily pretreated, triple-class refractory MM patients. Here, SLAMF7 is linked to Miyoshi myopathy.